Explore

TrendlineTrendline
Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth
TrendlineTrendline
Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses

Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses

Moderna Reports Q3 2026 Profit, Signaling Shift from Consistent Losses
TrendlineTrendline
Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline

Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline

Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline
TrendlineTrendline
Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline

Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline

Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline
TrendlineTrendline
Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance

Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance

Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
TrendlineTrendline
AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges
TrendlineTrendline
Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline
TrendlineTrendline
Anthropic's Biotech Expansion Faces Scientific Skepticism Over Cancer Cure Claims

Anthropic's Biotech Expansion Faces Scientific Skepticism Over Cancer Cure Claims

Anthropic's Biotech Expansion Faces Scientific Skepticism Over Cancer Cure Claims
TrendlineTrendline
FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies
TrendlineTrendline
Moderna Raises 2026 Outlook Amid Stronger Vaccine Sales and Cost Reductions

Moderna Raises 2026 Outlook Amid Stronger Vaccine Sales and Cost Reductions

Moderna Raises 2026 Outlook Amid Stronger Vaccine Sales and Cost Reductions
ReutersReuters
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas

Nov 6 (Reuters) - Moderna lifted its full-year revenue forecast on Friday, after strong international demand for its COVID-19 vaccine and payments from partnerships helped the biotech swing to profit in the third quarter.